Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
Randa Bascharon, Founder, President and Orthopedic Surgeon at Sports Performance Institute of Las Vegas, shared a post on LinkedIn:
“Wharton’s Jelly is increasingly discussed in orthopedic and sports medicine settings, particularly among active patients looking for non-surgical options.
Wharton’s Jelly is derived from donated umbilical cord tissue and contains growth factors and signaling proteins that may support the body’s healing environment.
In clinical practice, it is considered in select cases involving tendon injuries, ligament issues, or certain joint conditions.
A few practical points are important:
- First, it is not the same as a steroid injection.
- Second, it is different from platelet-rich plasma.
- Third, it is not a universal substitute for surgery.
Candidacy varies.
The decision to consider a biologic injection depends on the diagnosis, severity of tissue damage, functional goals, prior treatments, and imaging findings.
Thoughtful patient selection matters.
For athletes and active adults, the real question is not whether a treatment is popular.
It is whether it aligns with the biology of their specific injury and their long-term performance goals.
If you are seeing more patients ask about biologics, how are you approaching education and expectation setting in your practice?
Educational only.
A diagnosis and treatment plan require an in-person evaluation.”
See more in the gallery.
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children